Vaccine Choice Canada
The Strange Case of Bexsero®

From Section 4 of the Report on the Canada Vigilance Database

Bexsero® was approved for use in Canada in January of 2014 and first sold in Canada in February that year according to Health Canada’s Summary Basis of Decision (SBD) to Accept Bexsero. In the SBD Health Canada informs us, “Protection by the vaccine was inferred from immune responses against the four antigens of the vaccine.” This statement means efficacy for this vaccine has not been proven.

Furthermore, a Canadian study Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, published in 2012 concerning the incidence of the meningitis B strain cases in Ontario calls it a rare disease — 256 cases in Ontario in 10 years.

To read the full document, please click here (pdf format).

The post The Strange Case of Bexsero® appeared first on Vaccine Choice Canada.